3.1 Age and sex distribution PD predominantly affects individuals over the age of 60, with incidence rising sharply after the age of 70
While Novo Nordisk won FDA approval in 2019 for Rybelsus, an oral semaglutide formulation from Novo Nordisk
Which weight-management trials to read For weight specifically, the STEP program studied semaglutide and the SURMOUNT program studied tirzepatide
These interventions are not cosmetic tools, but targeted strategies designed to modulate underlying physiologic systems
For the first time, semaglutide, the active ingredient in Wegovy, may soon be available as a daily pill rather than a weekly injection
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
.webp)
